AI-powered collaborations drive billion-dollar deals, accelerating antibody design, biopharmaceuticals, and next-gen biologics development.Recent advancements in artificial intelligence (AI) technology present opportunities to enhance the antibody design process. Several biotechnology companies have emerged, integrating machine learning methods with laboratory technologies.

人工智能推动的合作推动了数十亿美元的交易，加速了抗体设计，生物制药和下一代生物制剂的开发。人工智能（AI）技术的最新进展为增强抗体设计过程提供了机会。一些生物技术公司已经出现，将机器学习方法与实验室技术相结合。

These companies generate data to assist in antibody design, analyze candidate antibodies, and perform rapid optimization. In the past year, numerous start-up biotech firms have attracted large pharmaceutical companies for collaboration in developing next-generation antibody drugs.Biotech and Pharma Partner to Drive Novel Antibody DevelopmentAI accelerates antibody design by generating data to assist in rapid iterative optimization.

这些公司生成数据以帮助抗体设计，分析候选抗体并进行快速优化。在过去的一年中，许多初创生物技术公司吸引了大型制药公司合作开发下一代抗体药物。生物技术和制药合作伙伴推动新型抗体开发AI通过生成数据来加速抗体设计，以帮助快速迭代优化。

The advancement of biopharmaceutical technology drives innovation in antibody design methods. Traditionally, therapeutic antibody discovery has required extensive screening of numerous candidates generated by immunizing animals or using phage expression techniques. This process has often proved time-consuming and complex, sometimes failing to produce antibodies with the desired properties.Given this vast area of opportunity, pharma companies are more regularly seeking out partnerships and collaborations to carve out their impact zone in the industry.

生物制药技术的进步推动了抗体设计方法的创新。传统上，治疗性抗体的发现需要广泛筛选通过免疫动物或使用噬菌体表达技术产生的许多候选物。该过程通常被证明是耗时且复杂的，有时无法产生具有所需特性的抗体。鉴于这一巨大的机会领域，制药公司更经常地寻求合作伙伴关系和合作，以开拓其在行业中的影响区域。

For example, in December 2023, AstraZeneca and AbbVie signed collaboration agreements exceeding $200 million with Absci and BigHat Biosciences, respectively. These partnerships aim to combine AI-powered antibody design platforms with pharmaceutical expertise to expedite the development of novel antibody therapies.For instance, AstraZeneca’s collaboration with Absci leverages the Integrated Drug Creation platform to optimize an.

例如，2023年12月，阿斯利康和艾伯维分别与Absci和BigHat Biosciences签署了超过2亿美元的合作协议。这些伙伴关系旨在将AI支持的抗体设计平台与药物专业知识相结合，以加速新型抗体疗法的开发。例如，阿斯利康与Absci的合作利用综合药物创建平台来优化。

Similarly, Generate, founded in 2018, has raised nearly $750 million and plans to use diffusion models for next-generation biologics design. More specifically, Generate, a clinical-stage biotherapeutics company, recently announced that it has raised $273 million in Series C financing. This funding round welcomed several new investors, including Amgen, NVentures (NVIDIA’s venture capital arm), MAPS Capital (Mirae Asset Group), and Pictet Alternative Advisors.

同样，成立于2018年的Generate已筹集近7.5亿美元，并计划将扩散模型用于下一代生物制剂设计。更具体地说，临床阶段的生物治疗公司Generate最近宣布，它已经在C系列融资中筹集了2.73亿美元。这轮融资欢迎了几位新投资者，包括安进（Amgen）、NVentures（NVIDIA的风险投资部门）、MAPS capital（Mirae Asset Group）和Pictet Alternative Advisors。

Company founder Flagship Pioneering and all Series B investors, such as a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., ARCH Venture Partners, and March Capital, also participated in the round.Biopharmaceutical giants are increasingly partnering with companies dedicated to AI in antibody design, signaling a new era of AI-driven development.

公司创始人旗舰创业者和所有B系列投资者，如阿布扎比投资管理局（ADIA）的全资子公司，富达管理与研究公司，T.Rowe Price Associates，Inc.，ARCH Venture Partners和March Capital咨询的基金和账户，也参加了这轮投资。生物制药巨头越来越多地与致力于抗体设计的AI公司合作，标志着AI驱动开发的新时代。

As these collaborations deepen, AI’s role in antibody design and biologics development will grow, potentially leading to innovative and effective treatments.Sanofi and BioMap’s $1 Billion Bet in Target-Specific Antibodies & Biologics DesignIn October 2023, Sanofi and BioMap announced a collaboration worth over $1 billion to develop AI models for biotherapeutic discovery.

随着这些合作的深化，人工智能在抗体设计和生物制剂开发中的作用将增长，可能导致创新和有效的治疗。赛诺菲和BioMap在目标特异性抗体和生物制剂设计方面的10亿美元赌注2023年10月，赛诺菲和BioMap宣布了一项价值超过10亿美元的合作，以开发用于生物治疗发现的人工智能模型。

BioMap, founded in 2020, uses AI platforms to drive drug discovery. The partnership combines Sanofi’s biologics engineering expertise with BioMap’s xTrimo models for antibody design and optimization. Under this agreement, BioMap received a $10 million upfront payment and could earn over $1 billion in milestone payments.

BioMap成立于2020年，利用人工智能平台推动药物发现。该合作关系将赛诺菲的生物制剂工程专业知识与BioMap的xTrimo抗体设计和优化模型相结合。根据这项协议，BioMap收到了1000万美元的预付款，可以获得超过10亿美元的里程碑付款。

This collaboration highlights the growing role of AI in antibody design and broader biologics development. The biotechnology and pharmaceutical industries are increasingly .

这种合作突出了AI在抗体设计和更广泛的生物制剂开发中日益重要的作用。生物技术和制药行业越来越多。

Related Article

相关文章

Experts Gather to Explore New Horizons in Health Technology AssessmentBiogen and UCB Promising Phase-III Trial Data for Lupus; CAR T-Cell Therapy Another Autoimmune Treatment AvenueApple’s AirPods Pro 2: First Ever FDA-approved OTC Hearing Aid Technology

专家们聚集在一起探索健康技术评估的新视野Biogen和UCB有希望的狼疮III期试验数据；CAR T细胞疗法另一种自身免疫疗法AvenueApple的AirPods Pro 2：首次获得FDA批准的OTC助听器技术

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]

©www.geneonline.com保留所有权利。与我们合作：[受电子邮件保护]